ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm. Its preclinical program include IMGC936, an investigational ADC in co-development with MacroGenics, Inc. ImmunoGen, Inc. has collaborations with Roche; Amgen/Oxford BioTherapeutics; sanofi-aventis U. S. LLC; Biotest AG; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Takeda Pharmaceutical Company Limited; Fusion Pharmaceuticals Inc.; Debiopharm International SA; Jazz Pharmaceuticals Ireland Limited; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
IPO Year: 1989
Exchange: NASDAQ
Website: immunogen.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/1/2023 | $25.00 → $31.00 | Buy → Neutral | Guggenheim |
| 11/20/2023 | $17.00 | Neutral | Goldman |
| 11/9/2023 | $25.00 | Buy | Deutsche Bank |
| 10/6/2023 | $16.00 | Perform | Oppenheimer |
| 5/3/2023 | $6.00 → $16.00 | Neutral → Overweight | Piper Sandler |
| 11/21/2022 | $10.00 | Buy | Truist |
| 9/9/2022 | $8.00 | Overweight | Barclays |
| 3/21/2022 | $9.00 → $6.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 2/22/2022 | $7.00 → $5.00 | Market Perform | SVB Leerink |
| 2/11/2022 | Outperform | BMO Capital |
Guggenheim downgraded ImmunoGen from Buy to Neutral and set a new price target of $31.00 from $25.00 previously
Goldman initiated coverage of ImmunoGen with a rating of Neutral and set a new price target of $17.00
Deutsche Bank initiated coverage of ImmunoGen with a rating of Buy and set a new price target of $25.00
Oppenheimer initiated coverage of ImmunoGen with a rating of Perform and set a new price target of $16.00
Piper Sandler upgraded ImmunoGen from Neutral to Overweight and set a new price target of $16.00 from $6.00 previously
Truist initiated coverage of ImmunoGen with a rating of Buy and set a new price target of $10.00
Barclays initiated coverage of ImmunoGen with a rating of Overweight and set a new price target of $8.00
RBC Capital Mkts downgraded Immunogen from Outperform to Sector Perform and set a new price target of $6.00 from $9.00 previously
SVB Leerink reiterated coverage of Immunogen with a rating of Market Perform and set a new price target of $5.00 from $7.00 previously
BMO Capital initiated coverage of Immunogen with a rating of Outperform
For Immediate Release: March 26, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Monday, the FDA proposed a ban of electrical stimulation devices intended to reduce or stop self-injurious or aggressive behavior, a step rarely taken by the agency. The agency has determined that these devices present an unreasonable and substantial risk of
Submission status for IMMUNOGEN INC's drug ELAHERE (SUPPL-5) with active ingredient MIRVETUXIMAB SORAVTANSINE-GYNX has changed to 'Approval' on 03/22/2024. Application Category: BLA, Application Number: 761310, Application Classification:
Submission status for IMMUNOGEN INC's drug ELAHERE (ORIG-1) with active ingredient MIRVETUXIMAB SORAVTANSINE-GYNX has changed to 'Approval' on 11/14/2022. Application Category: BLA, Application Number: 761310, Application Classification:
Submission status for IMMUNOGEN INC's drug MIRVETUXIMAB SORAVTANSINE (ORIG-1) with active ingredient MIRVETUXIMAB SORAVTANSINE has changed to 'Approval' on 11/14/2022. Application Category: BLA, Application Number: 761310, Application Classification: